News #MSParis2017 – Researchers Suggest Propionic Acid Could Be Used as Add-on Treatment in MS #MSParis2017 – Researchers Suggest Propionic Acid Could Be Used as Add-on Treatment in MS by Patricia Silva, PhD | October 25, 2017 Share this article: Share article via email Copy article link Propionic acid supplements alter the composition and behavior of immune cells in multiple sclerosis (MS) patients ā likely by changing the composition of gut bacteria, according to Alexander Duscha from Ruhr University BochumĀ in Bochum, Germany. The finding, presented Wednesday at the 7th Joint ECTRIMS-ACTRIMS MeetingĀ running in Paris through Oct. 28, provides yet another piece of evidence supporting an important role for gut bacteria in modulating the immune system in MS. The study, āPropionic acid modulates T effector cell balance and function in MS patients,ā was presented at the meeting as part of the Young Scientific Investigators’ Session. The researchers had previously studied propionic acid āĀ a fat component produced by certain gut bacteria āĀ in an animal model of MS. Their studies indicated that the fatty acid could slow the disease course in the animals. They also showed that mice fed a diet rich in propionic acid also developed a richer variety of gut bacteria. Since propionic acid is an approved food additive, the team went on to conduct a study of the compound in human MS patients. Duscha and his colleagues recruited 90 MS patients and 30 healthy people as controls, giving them 500 mg of propionic acid twice daily for 14 to 90 days. The MS patients were all receiving various disease-modifying therapies. After 14 days, they noted a drop in inflammatory T-cell numbers in both patients and controls, but with a more pronounced reduction in MS patients. Meanwhile, the number of regulatory T-cells, or Tregs, increased by 30 percent. Tregs are important cells that prevent autoimmune reactions, and according toĀ Duscha, the “suppressive capacity of Tregs in MS is diminished by 20 percent.” Researchers also noted that Tregs were better at modulating immune responses after propionic acid treatment in MS patients. “After only 14 days of propionate treatment, the suppressive capacity [of Tregs] was highly increased,”Ā Duscha said. Analyzing the types of gut bacteria in MS patients and controls, the team noted significant differences, particularly with relapsing-remitting MS (RRMS) patients having a lower diversity of gut bacterial types. “Microbiome analysis on stool samples demonstrates differences between MS and healthy controls, but also between RRMS and primary progressive (PPMS) and secondary progressive MS (SPMS) in terms of variability, both before and after treatment.” Regarding safety, patients did not report any side effects of propionic acid treatment during the study. Overall, the study’s results indicate that the findings in mice are also valid in people with MS, and suggest propionic acid could be a valuable supplement to be used as an add-on therapy to disease-modifying drugs. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags #MSParis2017, gut bacteria, microbiome, regulatory T-cells, T-cells, Tregs
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8